MedWorm: Cutaneous T cell lymphoma

[News] Infection risk not increased with alemtuzumab

The Lancet Oncology — Wed, 01 Feb 2012 05:00:00 +0100

Alemtuzumab clears circulating B and T lymphocytes and effectively treats leukaemic cutaneous T-cell lymphoma (L-CTCL). However, remarkably, it does not seem to increase patients' risk of infection, because resident populations of non-malignant effector memory T cells (TEMs) in the skin are spared, while malignant central memory T cells (TCMs) that recirculate between skin and blood are cleared, US researchers report. Mycosis fungoides, a skin-resident TEM malignancy, is unaffected by alemtuzumab. (Source: The Lancet Oncology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Increased Twist expression in advanced stage of Mycosis fungoides and Sézary syndrome

Journal of Cutaneous Pathology — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages. (Source: Journal of Cutaneous Pathology)

Allos Therapeutics reports interim data of Folotyn combination therapy

Drug Development Technology — Tue, 31 Jan 2012 00:00:00 +0100

Allos Therapeutics has announced the interim results from the ongoing Phase 1 combination study of Folotyn (pralatrexate injection) and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology)

A Leukemia Drug Kills Cancerous T-Cells While Sparing Normal Immunity

Health News from Medical News Today — Fri, 27 Jan 2012 08:00:00 +0100

Leukemic cutaneous T-cell lymphoma (L-CTCL) is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years. Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues now report a new study that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections... (Source: Health News from Medical News Today)

Annular Hypopigmented Mycosis Fungoides: A Novel Ringed Variant

Journal of Cutaneous Pathology — Fri, 27 Jan 2012 05:27:49 +0100

We present a novel and unique clinical presentation in an African‐American female patient, consisting of regular hypopigmented annular rings in areas of normal skin and in more typical hypopigmented patches of mycosis fungoides. The lesions appeared diffusely on all extremities, anterior chest, and back. Histopathologic examination showed an atypical lymphocytic infiltrate at the dermal‐epidermal junction with epidermotropism and few Pautrier's collections. The patient was otherwise healthy and improved with narrowband ultraviolet (UV)‐B. This case represents a presentation of a most unusual variant of hypopigmented mycosis fungoides, for which we propose the name “annular hypopigmented mycosis fungoides.” (Source: Journal of Cutaneous Pathology)

Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Cochrane Database of Systematic Reviews — Thu, 26 Jan 2012 08:18:08 +0100

CONCLUSIONS: We planned to report evidence from genetically or non-genetically randomised controlled trials comparing conventional therapy and allogeneic stem cell transplantation. However, no randomised trials addressing this question were identified. Nevertheless, prospective genetically randomised controlled trials need to be initiated to evaluate the precise role of alloSCT in advanced CTCL. PMID: 22258991 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A leukemia drug kills cancerous T-cells while sparing normal immunity

EurekAlert! - Medicine and Health — Wed, 25 Jan 2012 05:00:00 +0100

(Brigham and Women's Hospital) Researchers report that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections. (Source: EurekAlert! - Medicine and Health)

Efficacy of narrowband ultraviolet B twice weekly for hypopigmented mycosis fungoides in Asians

Clinical And Experimental Dermatology — Wed, 25 Jan 2012 05:00:00 +0100

SummaryHypopigmented mycosis fungoides (MF) is a rare variant of cutaneous T‐cell lymphoma. To date, there have been no data published about the efficacy of a twice‐weekly regimen of narrowband ultraviolet B (NB‐UVB) for the treatment of hypopigmented MF. We retrospectively reviewed 11 patients with hypopigmented MF who were treated with NB‐UVB twice weekly between 2001 and 2010. Of the 11 patients, 7 achieved a complete response with a mean of 40 treatments; the remaining 4 patients had a partial response. Upon discontinuation of treatment, three patients had clinical relapse after complete remission. Median time to relapse was 10 months. A twice‐weekly regimen of NB‐UVB is an effective treatment for hypopigmented MF with minimal side‐effects. However, the relapse rate is ...

A Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity

BWH for Journalists — Wed, 25 Jan 2012 00:00:00 +0100

Campath not only treats patients with L-CTCL but does so without increasing their risk of infections. (Source: BWH for Journalists)

A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations.

International Journal of Hematology — Fri, 20 Jan 2012 05:00:00 +0100

We report here a case involving a 28-year-old female patient with mycosis fungoides who underwent umbilical cord blood transplantation three times and developed CMV ventriculoencephalitis. The patient's CMV viremia was successfully preempted with ganciclovir (GCV) as indicated by undetectable CMV antigenemia; despite this successful treatment, the patient developed CMV ventriculoencephalitis. Foscarnet (FCV) therapy led to a temporary recovery, after which CMV ventriculoencephalitis recurred, and the patient died after receiving combination GCV and FCV therapy. Autopsy samples revealed CMV ventriculoencephalitis, as indicated by numerous inclusion-bearing cells (Owl's eye). It is likely that this patient harbored a GCV-resistant CMV strain; however, it was not possible to obtain nucleic ac...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Study Published On Novel Treatment For Skin Lymphoma

Health News from Medical News Today — Wed, 18 Jan 2012 10:00:00 +0100

Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are published in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine. The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine)... (Source: Health News from Medical News Today)

Lymphomatoid papulosis: Clinical and pathological findings in 18 patients.

Actas Dermo-Sifiliograficas — Tue, 17 Jan 2012 05:00:00 +0100

CONCLUSION: LyP is typically a CD30(+) lymphoproliferative disorder that usually runs a benign course and responds well to treatment. PMID: 22261676 [PubMed - as supplied by publisher] (Source: Actas Dermo-Sifiliograficas)

Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides Type [Study]

Archives of Dermatology — Mon, 16 Jan 2012 05:00:00 +0100

Conclusion O6-benzylguanine significantly depletes O6-alkylguanine-DNA alkyltransferase in CTCL lesions and in combination with topical carmustine is well tolerated and shows meaningful clinical responses in CTCL at markedly reduced total carmustine treatment doses. Trial Registration clinicaltrials.gov Identifier: NCT00003613 (Source: Archives of Dermatology)

Cutaneous Manifestations of DOCK8 Deficiency Syndrome [Observation]

Archives of Dermatology — Mon, 16 Jan 2012 05:00:00 +0100

Conclusions DOCK8 deficiency and Job's syndrome share several clinical features, including elevated serum IgE levels, dermatitis, recurrent sinopulmonary infections, and cutaneous staphylococcal abscesses. However, the presence of recalcitrant, widespread cutaneous viral infections, asthma, and food and environmental allergies, as well as the absence of newborn rash and coarse facies, favors the clinical diagnosis of DOCK8 deficiency. Rates of malignancy and overall mortality in patients with DOCK8 deficiency were higher than in those with Job's syndrome, highlighting the value of distinguishing between these conditions and the importance of close monitoring for neoplasia. (Source: Archives of Dermatology)

The beauty of TLR agonists for CTCL

Blood — Thu, 12 Jan 2012 05:00:00 +0100

(Source: Blood)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

Blood — Thu, 12 Jan 2012 05:00:00 +0100

This study is registered at www.clinicaltrials.gov as NCT00226993. (Source: Blood)

Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides and disease control by ifn-a and puva therapy.

The British Journal of Dermatology — Wed, 11 Jan 2012 05:00:00 +0100

Conclusions: Our data seem to indicate that CTACK/CCL27 levels in skin and sera after therapy might be correlated with risk of recurrence. PMID: 22233400 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides and disease control by ifn‐a and puva therapy.

British Journal of Dermatology — Wed, 11 Jan 2012 05:00:00 +0100

Conclusions: Our data seem to indicate that CTACK/CCL27 levels in skin and sera after therapy might be correlated with risk of recurrence. (Source: British Journal of Dermatology)

Case report demonstrating use of an expanded immunohistochemical panel to distinguish cutaneous hodgkin lymphoma from histopathologic imitators

Journal of Cutaneous Pathology — Tue, 10 Jan 2012 05:00:00 +0100

We report a 40‐year‐old man with classical Hodgkin lymphoma who developed cutaneous nodules. A biopsy from one revealed Hodgkin/Reed‐Sternberg cells with a similar immunophenotype to the diagnostic lymph node biopsy, namely CD30+/CD15+, diffusely but weakly PAX5+, focally weakly Oct‐2+, and lacking BOB.1 expression, thereby confirming a diagnosis of cutaneous Hodgkin lymphoma. To our knowledge, this is the first report of the expression of the combination of PAX5, Oct‐2, and BOB.1 in the context of cutaneous involvement by Hodgkin lymphoma. (Source: Journal of Cutaneous Pathology)

Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis

Journal of the European Academy of Dermatology and Venereology — Mon, 09 Jan 2012 05:00:00 +0100

Conclusion The present study confirms that topical nitrogen mustard is a safe and effective therapy. The treatment response in patients with parapsoriasis was not statistically different from the response in patients with MF. This supports, that parapsoriasis is not a distinct entity, but an early stage of MF. Nitrogen mustard should therefore still be considered as an important treatment modality in patients with early stages (parapsoriasis) and later stages of MF either as monotherapy or in combination with other topical or systemic therapies. (Source: Journal of the European Academy of Dermatology and Venereology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T cell lymphoma patients

American Journal of Hematology — Sun, 01 Jan 2012 05:00:00 +0100

AbstractRomidepsin is the second histone deacytelase inhibitor (HDACi) approved for the treatment of advanced stages of cutaneous T cell lymphoma (CTCL). Recent in vitro data suggests that HDACi suppress immune function although these findings have not been confirmed in patients. Thus, we serially examined the cellular immune function of eight CTCL patients undergoing treatment with three cycles of romidepsin. We measured the patient's natural killer (NK) and dendritic cell (DC) function, and performed an in vitro TUNEL assay to measure cellular apoptosis. Patients' NK cell cytolytic activity decreased from baseline to the third cycle of treatment (P=.018) but stimulation with a TLR agonist increased this activity (P=.018). At baseline a TLR agonist could both activate patients' DC (P=.043...

[Syringotropic cutaneous T-cell lymphoma mimicking dermatomycosis].

Annales de Dermatologie et de Cenereologie — Sun, 01 Jan 2012 05:00:00 +0100

We report a case involving a misleading cutaneous presentation on the sole of the foot. PATIENTS AND METHODS: A 55-year-old woman presented discrete coalescent papules on her left foot, having an anhidrotic appearance, for which a number of antifungal treatments had been given without success. The skin biopsy revealed CD4+ T lymphocytic dermal infiltrate, mainly near the sweat glands, with syringotropism. The diagnosis of syringotropic T-cell lymphoma was reinforced by the presence of dominant cutaneous T-lymphocyte clone in the skin biopsy. Staging tests were negative. Treatment was initiated with an extremely potent (class IV) dermal corticosteroid. DISCUSSION: Syringotropic T-cell lymphoma is an extremely rare form of cutaneous lymphoma similar in presentation to mycosis fungoid...

[New developments in Sézary syndrome].

Annales de Dermatologie et de Cenereologie — Sun, 01 Jan 2012 05:00:00 +0100

Authors: Caudron A, Marie-Cardine A, Bensussan A, Bagot M Abstract Sézary syndrome (SS) represents 3% of cutaneous T-cell lymphomas (CTCL). It is an aggressive epidermotropic CTCL with a 5-year survival rate of 24%. According to EORTC (European organization for research and treatment of cancer), SS is defined by erythroderma, diffuse lymphadenopathy, atypical T lymphocytes (>1000/mm(3)), and the presence of a major blood, cutaneous and nodal T cell clone. A specific marker for atypical tumoral T lymphocytes known as Sézary cells was identified in 2001, namely KIR3DL2 (CD158k) receptor, which allows more specific diagnosis of SS; levels of this marker are highly correlated with the clinical course of the disease. In therapeutic terms, clinical trials are being conducted on n...

Primary Cutaneous CD4+ Pleomorphic T-Cell LymphomaPrimary Cutaneous CD4+ Pleomorphic T-Cell Lymphoma

Medscape Today Headlines — Thu, 29 Dec 2011 04:00:00 +0100

The authors present 5 cases of primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma, a rare, but prognostically favorable, provisional subcategory of cutaneous T-cell lymphoma. American Journal of Clinical Dermatology (Source: Medscape Today Headlines)

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

Cancer Chemotherapy and Pharmacology — Wed, 28 Dec 2011 16:45:19 +0100

Conclusion Combination of bortezomib, gemcitabine, and liposomal doxorubicin is well tolerated, but with a lower recommended phase II dose in elderly patients, and demonstrated antitumor activity, especially in T-cell and small cell histology malignancies. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1808-4Authors G. S. Falchook, Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAM. Duvic, Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAD. S. Hong, Divis...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma

American Journal of Clinical Dermatology — Thu, 22 Dec 2011 06:03:30 +0100

(Source: American Journal of Clinical Dermatology)

Hypopigmented Mycosis Fungoides in Type V Skin: A Report of 5 Cases

Journal of Biophysics — Tue, 20 Dec 2011 13:20:46 +0100

Five patients with type V skin were studied to describe the clinical manifestations, pathological features, and treatment response in hypopigmented mycosis fungoides (HMF). The mean age of patients was 22.4 years at diagnosis, with a mean of 36 months of diagnostic delay. Two were children aged 11 and 13 years. Skin patches were limited to sunlight-covered body areas. In tropical climate, exposure to natural sunlight possibly cured the lesions on sun-exposed areas at early stage of onset. HMF may frequently be misinterpreted as eczema, vitiligo, or progressive macular hypomelanosis clinically and histopathologically as seen in our case series. (Source: Journal of Biophysics)

High Clinical Response Rate of Sezary Syndrome to Immunomodulatory Therapies: Prognostic Markers of Response [Study]

Archives of Dermatology — Mon, 19 Dec 2011 05:00:00 +0100

Conclusions In this large cohort study of patients with SS, a high clinical response rate was achieved using multiple immunomodulatory therapies. A lower CD4/CD8 ratio, a higher percentage of monocytes, and lower numbers of circulating abnormal T cells at baseline were the strongest predictive factors for complete response compared with nonresponse and warrant further examination in a larger cohort. (Source: Archives of Dermatology)

Childhood mycosis fungoides: a report of 20 cases from Turkey

Journal of the European Academy of Dermatology and Venereology — Mon, 19 Dec 2011 05:00:00 +0100

Conclusion In our experience, patches were more prevalent among childhood MF cases. Overrepresentation of hypopigmented and purpuric lesions was remarkable. Progression to an advanced stage was not seen. However, recurrences after discontinuation of therapy were common. (Source: Journal of the European Academy of Dermatology and Venereology)

Granulomatous and eccrinotropic lymphomatoid papulosis

Indian Journal of Dermatology, Venereology and Leprology — Sat, 17 Dec 2011 05:00:00 +0100

Nilam Jain, Rameshwar Gutte, Pinanky Jadhav, Uday KhopkarIndian Journal of Dermatology, Venereology, and Leprology 2012 78(1):82-84Lymphomatoid papulosis has been classically described as a chronic, recurrent and self-healing papulonecrotic or papulonodular skin eruption, which is clinically benign and histopathologically malignant. The histologic characteristics of lymphomatoid papulosis are suggestive of a cluster of differentiation 30+ (CD30+) malignant lymphoma, and it is best regarded as a low grade cutaneous T cell lymphoma (CTCL). We hereby report a case of granulomatous and eccrinotropic lymphomatoid papulosis in a 40- year-old male. There was no systemic involvement. The patient was treated with low dose oral methotrexate with good response. (Source: Indian Journal o...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Photodynamic Therapy with Methyl-aminolaevulinic Acid for Mycosis Fungoides.

Acta Dermato-Venereologica — Thu, 15 Dec 2011 05:00:00 +0100

In conclusion, PDT with MAL is a fast, effective and well-tolerated treatment for unilesional mycosis fungoides. PMID: 22170261 [PubMed - as supplied by publisher] (Source: Acta Dermato-Venereologica)

Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution?

Pediatric Blood and Cancer — Tue, 13 Dec 2011 01:39:08 +0100

(Source: Pediatric Blood and Cancer)

Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution

Pediatric Blood and Cancer — Tue, 13 Dec 2011 01:39:06 +0100

(Source: Pediatric Blood and Cancer)

Identification of Selective Class II Histone Deacetylase Inhibitors Using a Novel Dual-Parameter Binding Assay Based on Fluorescence Anisotropy and Lifetime

Journal of Biomolecular Screening — Mon, 12 Dec 2011 05:00:00 +0100

In this study, a dual-competition assay exploiting changes in fluorescence anisotropy and lifetime was used to screen the LOPAC (Sigma-Aldrich, St Louis, MO) library against the bacterial histone deacetylase homologue HDAH from Bordetella, which shares 35% identity with the second deacetylase domain of HDAC6. The binding assay proved to be highly suitable for high-throughput screening campaigns. Several LOPAC compounds have been identified to inhibit HDAH in the lower micromolar range. Most interestingly, some of the hit compounds turned out to be weak but selective inhibitors of human class IIa and IIb HDACs. (Source: Journal of Biomolecular Screening)

The Four Types of Tregs in Malignant Lymphomas

Journal of Hematology and Oncology — Fri, 09 Dec 2011 05:00:00 +0100

Regulatory T cells (Tregs) are a specialized subpopulation of CD4+ T cells, which act to suppress the activation of other immune cells. Tregs represent important modulators for the interaction between lymphomas and host microenvironment. Lymphomas are a group of serious and frequently fatal malignant diseases of lymphocytes. Recent studies revealed that some lymphoma T cells might adopt a Treg profile. Assessment of Treg phenotypes and genotypes in patients may offer prediction of outcome in many types of lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, cutaneous T cell lymphoma, and Hodgkin's lymphoma. Based on characterized roles of Tregs in lymphomas, we can categorize the various roles into four groups: (a) suppressor Tregs; (b) malignant Tregs; (c) direct tumor-...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets

Journal of the European Academy of Dermatology and Venereology — Thu, 08 Dec 2011 05:00:00 +0100

Conclusion The study’s findings demonstrate that the studied hypopigmented (vitiligo, hypopigmented MF, hypopigmented TV) disorders show similar changes in their cutaneous microenvironment with increased TNF‐α and decreased bFGF mRNA expression. This cytokine microenvironment change may be implicated in the pigment loss and hence these cytokines may have future therapeutic implications. (Source: Journal of the European Academy of Dermatology and Venereology)

Sezary Syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.

Dermatol Online J — Wed, 07 Dec 2011 17:30:03 +0100

We present the case of a 54-year-old man with Sezary syndrome presenting with leonine facies, unresponsive to conventional therapies; he exhibited a promising response to subcutaneous low-dose alemtuzumab. PMID: 22136862 [PubMed - in process] (Source: Dermatol Online J)

Peroxisome proliferator‐activated receptor gamma, a possible culprit in mycosis fungoides: an immunohistochemical study

Journal of the European Academy of Dermatology and Venereology — Thu, 24 Nov 2011 05:00:00 +0100

Conclusion Our data suggest a possible role for PPARγ in the pathogenesis of MF possibly through several mechanisms, one of which might be conferring upon the lymphoma cells, a survival advantage at least partially through up regulating Bcl‐2. (Source: Journal of the European Academy of Dermatology and Venereology)

Early CTCL diagnosis, a (miR)age no more?

Blood — Thu, 24 Nov 2011 05:00:00 +0100

(Source: Blood)

Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

Blood — Thu, 24 Nov 2011 05:00:00 +0100

Cutaneous T-cell lymphomas (CTCLs) are the most frequent primary skin lymphomas. Nevertheless, diagnosis of early disease has proven difficult because of a clinical and histologic resemblance to benign inflammatory skin diseases. To address whether microRNA (miRNA) profiling can discriminate CTCL from benign inflammation, we studied miRNA expression levels in 198 patients with CTCL, peripheral T-cell lymphoma (PTL), and benign skin diseases (psoriasis and dermatitis). Using microarrays, we show that the most induced (miR-326, miR-663b, and miR-711) and repressed (miR-203 and miR-205) miRNAs distinguish CTCL from benign skin diseases with > 90% accuracy in a training set of 90 samples and a test set of 58 blinded samples. These miRNAs also distinguish malignant and benign lesions in an i...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Simplified flow cytometric assessment in mycosis fungoides and sezary syndrome.

American Journal of Clinical Pathology — Mon, 21 Nov 2011 13:30:41 +0100

Authors: Hristov AC, Vonderheid EC, Borowitz MJ Abstract By using flow cytometry with markers for CD3, CD4, CD26, and CD7, we examined the blood samples of 109 patients for abnormal T cells: 69 patients with mycosis fungoides (MF)/Sézary syndrome (SS), 31 hospitalized control subjects, and 9 patients with inflammatory skin disease. T cells were identified as quantitatively abnormal (>15% CD26- or CD7- T cells) or phenotypically abnormal (CD26- or CD7- T cells with bright or dim CD3 or CD4 or bright CD7). Patients were followed for a median of 82 months, and abnormal T cells were correlated with diagnosis, clinical outcome, and other laboratory parameters. Abnormal T-cell populations were identified in 46% of patients with MF/SS (32/69) and correlated with disease extent. Quanti...

Mycosis Fungoides in the Setting of T-cell Large Granular Lymphocyte Proliferative Disorder.

Acta Derm Venereol A... — Mon, 21 Nov 2011 05:00:00 +0100

Authors: Saggini A, Saraceno R, Anemona L, Chimenti S, Stefani AD PMID: 22101567 [PubMed - as supplied by publisher] (Source: Acta Derm Venereol A...)

Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma

Journal of Clinical Investigation — Thu, 17 Nov 2011 21:51:18 +0100

Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of non-Hodgkin lymphomas that affect the skin. The pathogenesis of these conditions is poorly understood. For example, the signaling mechanisms contributing to the dysregulated growth of the neoplastic T cells are not well defined. Here, we demonstrate that loss of nuclear localization of pro–IL-16 facilitates CTCL cell proliferation by causing a decrease in expression of the cyclin dependent–kinase inhibitor p27Kip1. The decrease in p27Kip1 expression was directly attributable to an increase in expression of S-phase kinase-associated protein 2 (Skp2). Regulation of Skp2 is in part attributed to the nuclear presence of the scaffold protein pro–IL-16. T cells isolated from 11 patients with advanced CT...

Author index∗

Journal of the American Academy of Dermatology — Wed, 16 Nov 2011 21:07:47 +0100

Abbott RA, Sahni D, Robson A, Agar N, Whittaker S, Scarisbrick JJ. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. 2011;65:313-9 (Original article) (Source: Journal of the American Academy of Dermatology)

OncoSec And Serametrix Collaborate To Identify Potential Biomarkers To Enhance Skin Cancer Immune Therapies

Pharmaceutical Online News — Wed, 16 Nov 2011 08:09:00 +0100

OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. (Source: Pharmaceutical Online News)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Expression of Thymidine Phosphorylase in Lymph Nodes Involved with Mycosis Fungoides and Sézary Syndrome

Journal of Biomedicine and Biotechnology — Mon, 14 Nov 2011 10:33:54 +0100

Thymidine phosphorylase may be overexpressed in both neoplastic cells and tumor stromal cells in a variety of malignancies. Our study explores thymidine phosphorylase expression in lymph nodes (LNs) from patients with mycosis fungoides (MF) or Sézary syndrome (SS). In MF/SS, the LNs may have a pathologic diagnosis of either dermatopathic lymphadenopathy (LN-DL) or involvement by MF/SS (LN-MF). We performed immunohistochemical staining on MF/SS lymph nodes using antibodies to thymidine phosphorylase, CD68, CD21, CD3, and CD4. In both LN-DL and benign nodes, thymidine phosphorylase staining was noted only in macrophages, dendritic cells, and endothelial cells. In LN-MF, thymidine phosphorylase expression was also noted in subsets of intermediate to large neoplastic T cells. Concurrent C...

Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T‐cell lymphoma and psoriasis in combination with serum thymus and activation‐regulated chemokine levels

Journal of the European Academy of Dermatology and Venereology — Mon, 14 Nov 2011 05:00:00 +0100

Conclusion Serum sCD26 levels, combined with serum TARC levels, are helpful in diagnosis of AD, CTCL and psoriasis. (Source: Journal of the European Academy of Dermatology and Venereology)

Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas.

The Oncologist — Wed, 09 Nov 2011 05:00:00 +0100

This study does not support a pathogenic role of B. burgdorferi in primary cutaneous B- and T-cell lymphomas from areas nonendemic for this microorganism and the consequent rationale for the adoption of antibiotic therapy in these patients. PMID: 22071292 [PubMed - as supplied by publisher] (Source: The Oncologist)

Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.

Chemical and Pharmaceutical Bulletin — Tue, 08 Nov 2011 05:50:03 +0100

In this study, we hypothesized that a liposomal formulation of HDACI might efficiently deliver HDACI into tumors. To incorporate HDACI efficiently into the liposomal membrane, we synthesized six HDACI-lipid conjugates, in which polyethylene glycol(2000) (PEG(2000))-lipid or cholesterol (Chol) was linked with a potent hydroxamic acid, HDACI, SAHA or K-182, by cleavable linkers, such as ester, carbamide and disulfide bonds. Liposomal HDACI-lipid conjugates were prepared with distearoylphosphatidylcholine (DSPC) and HDACI-Chol conjugate or with DSPC, Chol and HDACI-PEG-lipid conjugates, and their cytotoxicities were evaluated for human cervix tumor HeLa and mouse colon tumor Colon 26 cells. Among the liposomes, liposomal oleyl-PEG(2000)-SAHA conjugated with SAHA and oleyl-PEG(2000) via a carb...

Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literature

Journal of Cutaneous Pathology — Tue, 08 Nov 2011 05:00:00 +0100

We present the case of a 60‐year‐old male with known stage IA mycosis fungoides (MF) who developed a suspicious tumor within a pre‐existing lymphomatous plaque of the right forearm. Microscopy revealed an unusual mixed fibrohistiocytic proliferation as well as atypical intraepidermal and dermal lymphocytes. There was no evidence of large‐cell transformation. Histopathological, immunohistochemical and clinical clues suggest this lesion might not have represented a dermatofibroma, but rather a hitherto unreported dermatofibroma‐like process arising within a lesion of MF. The potential impact of this atypical lesion on the prognosis and clinical management of this patient highlights the importance of recognizing unusual clinical presentations of more common, benign lesions within th...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Mycosis fungoides stage IB progressing to cutaneous tumors.

Dermatol Online J — Tue, 08 Nov 2011 04:35:03 +0100

Authors: Berger E, Altiner A, Chu J, Patel R, Sanders S, Latkowski JA Abstract A 44-year-old African American woman presented with well-demarcated, pruritic and intermittently painful plaques and subsequently a diagnosis of mycosis fungoides stage IB was made. Six months after diagnosis, cutaneous tumors developed despite treatment with narrow-band ultraviolet B phototherapy. The patient failed low-dose methotrexate treatment and is now slowly improving on combination therapy with subcutaneous interferon alfa and oral bexarotene. This patient demonstrates the progression of patch/plaque stage disease to cutaneous tumors. Her case highlights the use of interferon and combination therapies in more advanced mycosis fungoides and demonstrates potential difficulties encountered in treat...

Erythrocyte sedimentation rate as an independent prognostic factor in Mycosis fungoides

British Journal of Dermatology — Mon, 07 Nov 2011 05:00:00 +0100

(Source: British Journal of Dermatology)

Radiation therapy in the management of unilesional primary cutaneous T‐cell lymphomas.

British Journal of Dermatology — Mon, 07 Nov 2011 05:00:00 +0100

Conclusion: Local radiation therapy appears to be an effective treatment for patients presenting with unilesional or localized cutaneous T‐cell lymphoma. (Source: British Journal of Dermatology)

Erythrocyte sedimentation rate as an independent prognostic factor in Mycosis fungoides.

The British Journal of Dermatology — Mon, 07 Nov 2011 05:00:00 +0100

Authors: Hallermann C, Niermann C, Fischer RJ, Schulze HJ PMID: 22059808 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas.

The British Journal of Dermatology — Mon, 07 Nov 2011 05:00:00 +0100

Conclusion: Local radiation therapy appears to be an effective treatment for patients presenting with unilesional or localized cutaneous T-cell lymphoma. PMID: 22059744 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Implications of Bax, Fas, and p53 in the pathogenesis of early-stage mycosis fungoides and alterations in expression following photochemotherapy

Indian Journal of Dermatology — Fri, 04 Nov 2011 04:00:00 +0100

Conclusion: Although Bax seems unrelated with early-stage MF, Fas and p53 expression in the lymphocytes may contribute to the understanding of the pathogenesis of this disease. (Source: Indian Journal of Dermatology)

IL-22, but not IL-17, Dominant Environment in Cutaneous T cell Lymphoma.

Clinical Cancer Research — Wed, 02 Nov 2011 04:00:00 +0100

CONCLUSIONS: Our results suggest that IL-22 is important in establishing the tumor microenvironment for CTCL. Enhanced expression of CCL20 may explain epidermal hyperplasia and migration of CCR6+ cells, such as Langerhans cells, into lesional skin. Relatively low expression of IL-17 may explain the lack of neutrophils in lesions of CTCL, which correlates with bacterial infections that commonly occur in skin affected by CTCL. PMID: 22048239 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Erythema annulare centrifugum-like mycosis fungoides.

The Australasian Journal of Dermatology — Tue, 01 Nov 2011 04:00:00 +0100

Authors: Ceyhan AM, Akkaya VB, Chen W, Bircan S Abstract A considerable number of recent reports have documented mycosis fungoides resembling many other dermatoses. Due to highly variable presentations and the sometimes non-specific nature of histological findings, an accurate diagnosis of mycosis fungoides can be difficult. Erythema annulare centrifugum-like mycosis fungoides with a variety of annular, polycyclic erythematous skin lesions is a recently recognized atypical manifestation of mycosis fungoides, and only a few cases have been reported to date. PMID: 22070716 [PubMed - in process] (Source: The Australasian Journal of Dermatology)

[Expression of psoriasin in mycosis fungoides and its significance].

Journal of Southern Medical University — Tue, 01 Nov 2011 04:00:00 +0100

CONCLUSION: Psoriasin may play a role in the pathogenesis of mycosis fungoides by chemotaxis of CD4+ T lymphocytes. PMID: 22126777 [PubMed - in process] (Source: Journal of Southern Medical University)

Unusual presentation of mycosis fungoides as a lump in the scalp.

Singapore Medical Journal — Tue, 01 Nov 2011 04:00:00 +0100

We report a case of mycosis fungoides in a 27-year-old woman who presented with a lump in the forehead. The condition was confirmed with tissue diagnosis. Gallium scintigraphy accurately delineated the complete extent of the disease, and served as a reference for objective assessment of response of the disease to treatment. PMID: 22173261 [PubMed - in process] (Source: Singapore Medical Journal)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas

Bone Marrow Transplantation — Mon, 24 Oct 2011 04:00:00 +0100

Authors: V R Paralkar, S D Nasta, K Morrissey, J Smith, P Vassilev, M E Martin, S C Goldstein, A Loren, A H Rook, E J Kim & D L Porter (Source: Bone Marrow Transplantation)

Inhibition of cell‐mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous t‐cell lymphoma

American Journal of Hematology — Sat, 22 Oct 2011 04:00:00 +0100

We describe a patient with Sezary syndrome who was monitored for drug‐induced immunosuppression while undergoing treatment with vorinostat,. Analysis of the patient's natural killer cell function before and after initiation of treatment confirmed inhibition of this important cell‐mediated immune function, In addition the in vitro effects of vorinostat on the immunity of healthy volunteers confirmed that this class of drug can profoundly suppress multiple arms of the cellular immune response. These findings raise concerns of increased susceptibility to infection in this high‐risk population. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc. (Source: American Journal of Hematology)

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

American Journal of Hematology — Sat, 15 Oct 2011 12:27:09 +0100

AbstractDisease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with si...

Adult T-cell lymphoma/leukemia presenting as pagetoid reticulosis of the palms and soles

Journal of the American Academy of Dermatology — Sat, 15 Oct 2011 05:13:23 +0100

To the Editor: A 40-year-old Jamaican man presented with a 6-month history of a pruritic eruption on his hands and feet. On examination, he had multiple, violaceous plaques on the palms and soles (). Biopsy revealed a lymphocytic infiltrate at the dermoepidermal junction with basal layer epidermotropism and pagetoid mononuclear cell infiltration (). The patient reported that he had been human T-cell lymphotropic virus type 1 (HTLV-1) positive since 2001.He was started on a regimen of PUVA therapy with a presumptive diagnosis of pagetoid reticulosis (Woringer-Kolopp) or mycosis fungoides palmaris et plantaris, a variant of cutaneous T-cell lymphoma. (Source: Journal of the American Academy of Dermatology)

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Blood — Thu, 13 Oct 2011 04:00:00 +0100

Primary cutaneous CD30+ lymphoproliferative disorders (CD30+ LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30+ LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international gu...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Rapid clinical change in lesions of atypical cutaneous lymphoproliferative disorder in an HIV patient: A case report and review of the literature.

Dermatol Online J — Mon, 10 Oct 2011 11:40:02 +0100

CONCLUSION: The working-theory of a reactive etiology for this condition might explain the evolution in appearance following initiation of HAART. The presence of papules with a dusky targetoid center suggests that this condition should be considered in the differential diagnosis with syphilis or atypical erythema multiforme in HIV patients. PMID: 21971269 [PubMed - in process] (Source: Dermatol Online J)

Low‐Dose Total Skin Electron Beam Therapy as a Debulking Agent for Cutaneous T‐Cell Lymphoma: An open‐label prospective phase II study

British Journal of Dermatology — Mon, 03 Oct 2011 04:00:00 +0100

Conclusions: Low‐dose TSEBT (10 Gy) had a satisfactory response rate and was well tolerated in patients with MF stage IB‐IV. Future studies should determine if the combination of low‐dose TSEBT with other agents could increase the rate of CR and response duration. (Source: British Journal of Dermatology)

Altered microRNA expression in mycosis fungoides

British Journal of Dermatology — Mon, 03 Oct 2011 04:00:00 +0100

Conclusions: Altered expression of studied microRNAs and the differences between early and advanced MF may suggest that microRNAs play a significant role in MF pathogenesis. It seems that microRNA could serve as potential therapeutic targets in the future. (Source: British Journal of Dermatology)

Low-Dose Total Skin Electron Beam Therapy as a Debulking Agent for Cutaneous T-Cell Lymphoma: An open-label prospective phase II study.

The British Journal of Dermatology — Mon, 03 Oct 2011 04:00:00 +0100

Conclusions: Low-dose TSEBT (10 Gy) had a satisfactory response rate and was well tolerated in patients with MF stage IB-IV. Future studies should determine if the combination of low-dose TSEBT with other agents could increase the rate of CR and response duration. PMID: 21967035 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

Altered microRNA expression in mycosis fungoides.

The British Journal of Dermatology — Mon, 03 Oct 2011 04:00:00 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas

Journal of Dermatological Science — Wed, 21 Sep 2011 04:00:00 +0100

Conclusion: Our data suggest Dicer expression as a possible molecular marker in patients with MF and apparently indicate that miRNA(s) might be of clinical relevance in CTCL. (Source: Journal of Dermatological Science)

Genetics: New miRNA classifier distinguishes CTCL from benign skin disorders

Nature Clinical Practice Oncology — Tue, 20 Sep 2011 04:00:00 +0100

Nature Reviews Clinical Oncology 8, 629 (2011). doi:10.1038/nrclinonc.2011.144 Author: Lisa Hutchinson Cutaneous T-cell lymphomas (CTCL) are the most frequently occurring primary skin lymphoma. These skin lesions contain a high number of inflammatory cells but early diagnosis of CTCL is challenging because of its clinical, pathological and histological similarity to benign inflammatory skin lesions such as psoriasis (Source: Nature Clinical Practice Oncology)

Cutaneous Manifestations of DOCK8 Deficiency Syndrome [Observation]

Archives of Dermatology — Mon, 19 Sep 2011 04:00:00 +0100

Congestive Heart Failure in a Patient With Cutaneous T-Cell Lymphoma Treated With Low-Dose Interferon Alfa-2b [Correspondence]

Archives of Dermatology — Mon, 19 Sep 2011 04:00:00 +0100

(Source: Archives of Dermatology)

CD4/CD8 double-negative early-stage mycosis fungoides associated with primary cutaneous follicular center lymphoma

Journal of the American Academy of Dermatology — Sun, 18 Sep 2011 01:35:53 +0100

To the Editor: There is a rare subgroup of patients with early mycosis fungoides (MF) that exhibits a CD4/CD8 double negative (DN) immunophenotype. The coexistence of MF and B-cell lymphomas in the same patient is also very unusual. To our knowledge, an early CD4/CD8 DN MF associated with cutaneous follicular center lymphoma in the same patient has never been reported. This association can be diagnostically challenging. (Source: Journal of the American Academy of Dermatology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS

Blood — Thu, 15 Sep 2011 04:00:00 +0100

Here we report that T-cell lymphoma cells carrying the NPM-ALK fusion protein (ALK+ TCL) frequently express the cell-stimulatory receptor ICOS. ICOS expression in ALK+ TCL is moderate and strictly dependent on the expression and enzymatic activity of NPM-ALK. NPM-ALK induces ICOS expression via STAT3, which triggers the transcriptional activity of the ICOS gene promoter. In addition, STAT3 suppresses the expression of miR-219 that, in turn, selectively inhibits ICOS expression. ALK+ TCL cell lines display extensive DNA methylation of the CpG island located within intron 1, the putative enhancer region, of the ICOS gene, whereas cutaneous T-cell lymphoma cell lines, which strongly express ICOS, show no methylation of the island. Treatment of the ALK+ TCL cell lines with DNA methyltransferas...

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome

Leukemia — Fri, 09 Sep 2011 04:00:00 +0100

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome Leukemia advance online publication, September 9, 2011. doi:10.1038/leu.2011.237 Authors: T Krejsgaard, N Odum, C Geisler, M A Wasik & A Woetmann (Source: Leukemia)

Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution?

Pediatric Blood and Cancer — Thu, 01 Sep 2011 23:00:00 +0100

(Source: Pediatric Blood and Cancer)

Newspath September, 2011 - Evaluation of Cutaneous T Cell Lymphomas with Molecular Techniques

NewsPath - Pathology News for the Medical Community — Thu, 01 Sep 2011 14:00:00 +0100

Molecular techniques provide powerful tools that have drastically changed our understanding of entire categories of neoplasms, including lymphomas. (Source: NewsPath - Pathology News for the Medical Community)

Actinic reticuloid--photosensitivity or pseudolymphoma?--A review.

Collegium Antropologicum — Thu, 01 Sep 2011 04:00:00 +0100

Authors: Lugović-Mihić L, Duvancić T, Situm M, Mihić J, Krolo I Abstract Actinic reticuloid (AR) or chronic actinic dermatitis is considered a sunlight-induced pseudolymphoma (PSL) on light exposed areas of the skin, which primarily affects elderly males. The disease is a severe, chronic photosensitive dermatosis, first described by Ive et al. in 1969. PSL is a group of non-cancerous lymphocytic skin disorders that simulate malignant lymphomas, but the changes usually spontaneously regress. The clinical appearance of Actinic reticuloid is variable, usually characterized by an eczematous, pruritic eruption, predominantly present on the head and neck, or other sun exposed areas, but can involve any area of the body. Thereby, crucial characteristic is photosensitivity, where at ac...

MedWorm Sponsor Message: Find the best January Sales in the UK.

The mechanisms of action of phototherapy in the treatment of the most common dermatoses.

Collegium Antropologicum — Thu, 01 Sep 2011 04:00:00 +0100

Authors: Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L Abstract Phototherapy denotes the use of ultraviolet (UV) light in the management of several dermatoses. Most phototherapy regimens utilize ultraviolet radiation of different wavelenghts. Currently, irradiations with broadband UVB (290-320 nm), narrowband UVB (311-313 nm), 308 nm excimer laser, UVA 1 (340-400 nm), UVA with psoralen (PUVA), and extracorporeal photochemotherapy (photopheresis) are being used. The interplay of the various photobiologic pathways is far from being completely understood. Disordes that may benefit from such approach are numerous, with psoriasis, atopic dermatitis, cutaneous T-cell lymphomas, morphea, and vitiligo as main indications. The immunomodulatory effects of UVB radiation primarily affect ...

Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Journal of Dermatological Science — Sun, 28 Aug 2011 23:00:00 +0100

Abstract: Sézary syndrome and erythrodermic mycosis fungoides have been recognized as part of a broader spectrum of erythrodermic cutaneous T-cell lymphoma (E-CTCL). Atopic dermatitis (AD) is the most common, chronic inflammatory skin disease and can, in its most severe form, manifest as erythroderma. It is often difficult to clinically distinguish E-CTCL from various common and benign diseases presenting as erythroderma, including AD. Differentiating E-CTCL from benign inflammatory diseases is important to ensure proper disease management, and to provide accurate prognostic information. Clinical and laboratory features, including pruritus and serum levels of soluble interleukin-2 receptor, lactate dehydrogenase (LDH), immunoglobulin E (IgE), and several chemokines, do not differentiate E...

Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30+ lymphoproliferative disorders: Immunohistochemical study of 43 samples

Journal of Dermatological Science — Thu, 25 Aug 2011 04:00:00 +0100

In this study, we analyzed the patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides (MF), Sezary syndrome (SS), CD30+ lymphoproliferative disorders (LPD) such as lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL), and inflammatory skin diseases. (Source: Journal of Dermatological Science)

Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

British Journal of Haematology — Wed, 24 Aug 2011 23:00:00 +0100

SummaryCutaneous T‐cell lymphomas (CTCL) are a heterogeneous group of malignancies derived from skin‐homing T cells. The most common forms of CTCL are Mycosis Fungoides (MF) and Sezary Syndrome (SS). Accurate diagnosis remains a challenge due to the heterogeneity of presentation and the lack of highly characteristic immunophenotypical and genetic markers. Over the past decade molecular studies have improved our understanding of the biology of CTCL. The identification of gene expression differences between normal and malignant T‐cells has led to promising new diagnostic and prognostic biomarkers that now need validation to be incorporated into clinical practice. These biomarkers may also provide insight into the mechanism of development of CTCL. Additionally, treatment options have ex...

Exiqon, LEO Pharma, Bispebjerg Hospital, Gentofte Hospital, Copenhagen University Hospital and University of Copenhagen Publish Validation of Biomarkers for Patients With Chronic Skin Diseases

Medical News (via PRIMEZONE) — Wed, 24 Aug 2011 14:57:00 +0100

VEDBAEK, Denmark, Aug. 24, 2011 (GLOBE NEWSWIRE) -- In a multicenter study, Exiqon, in collaboration with LEO Pharma, Bispebjerg Hospital, Gentofte Hospital, Copenhagen University Hospital and University of Copenhagen, has identified promising diagnostic biomarkers of cutaneous T cell lymphoma (CTCL) to distinguish between malignant and benign inflammation - i.e. between CTCL and chronic diseases such as psoriasis, atopic dermatitis and eczema. The results have been published in the well-esteemed journal "Blood, Journal of the American Society of Hematology", which is available at: http://bloodjournal.hematologylibrary.org/content/early/2011/08/23/blood-2011-06-358382 (Source: Medical News (via PRIMEZONE))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cutaneous involvement by colonic extranodal NK/T‐cell lymphoma mimicking mycosis fungoides: a case report*

Journal of Cutaneous Pathology — Mon, 22 Aug 2011 23:00:00 +0100

We report a 51‐year‐old woman with cutaneous involvement by extranodal NK/T‐cell lymphoma (TCL) of the colon that microscopically mimicked mycosis fungoides (MF). She had a history of fever of unknown origin for 2 months and then developed multiple erythematous papules on her trunk and extremities. A skin biopsy revealed superficial infiltration by atypical small to medium‐sized lymphocytes with epidermotropism and Pautrier collections. Immunohistochemical studies showed expression of CD3 and TIA‐1 with lack of expression (double negative) of CD4 and CD8. Initially, we reported the diagnosis as MF, cytotoxic variant. Thereafter, computerized tomography scan incidentally identified a colonic mass. A colonic biopsy revealed infiltration of atypical lymphoid cells with the same morp...

CD30+ Neoplasms of the Skin

Current Hematologic Malignancy Reports — Thu, 18 Aug 2011 06:02:56 +0100

Abstract Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma. After MF/SS, the next most common CTCLs are CD30+ lymphoproliferative disorders: self-regressing lymphomatoid papulosis (LyP) or tumors of anaplastic large-cell lymphoma (ALCL), which express high levels of tumor necrosis factor death receptor member 8, also called CD30. Although MF is not considered to be a CD30+ lymphoproliferative disorder, MF may co-exist with LyP lesions, and MF may express CD30, especially in the setting of large-cell transformation...

Triple Therapy Leads To Remission In Cutaneous Lymphoma

Health News from Medical News Today — Tue, 16 Aug 2011 07:00:00 +0100

A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. In a retrospective study of 98 patients with advanced Sezary Syndrome treated over a 25 year time span at the Hospital of the University of Pennsylvania patients treated with combination therapy experienced a higher overall response rate compared to previous studies (74.4 percent vs... (Source: Health News from Medical News Today)

Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission

EurekAlert! - Medicine and Health — Mon, 15 Aug 2011 04:00:00 +0100

(University of Pennsylvania School of Medicine) A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Medicine and Health)

High Clinical Response Rate of Sezary Syndrome to Immunomodulatory Therapies: Prognostic Markers of Response [Study]

Archives of Dermatology — Sun, 14 Aug 2011 23:00:00 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Persistent agmination of lymphomatoid papulosis: A new case with immunohistopathologically confirmed mycosis fungoides component

Journal of the American Academy of Dermatology — Fri, 12 Aug 2011 16:59:57 +0100

To the Editor: A number of studies have demonstrated an association between mycosis fungoides (MF) and lymphomatoid papulosis (LyP); simultaneous intralesional appearance of these entities, however, is unique. Recently Heald et al reported a series of 7 patients with typical patch(es) and plaque(s) of MF with histologically confirmed intralesional papulonodules of LyP, suggesting it to be a new distinct entity. (Source: Journal of the American Academy of Dermatology)

Folliculotropic mycosis fungoides following renal transplantation

Journal of the American Academy of Dermatology — Fri, 12 Aug 2011 16:59:56 +0100

To the Editor: A 46-year-old Caucasian man presented to the Johns Hopkins Transplant Dermatology Clinic for recurrence of eczematous dermatitis 2 years after living-unrelated renal transplantation for polycystic kidney disease. He had mild dermatitis for 4 years preceding transplantation that resolved after transplantation. His medications included mycophenolate mofetil 2 grams per day and cyclosporine 300 to 350 mg per day. Clinical evaluation revealed eczematous, erythematous weeping plaques, perifollicular pustules and several deep-seated 2- to 3-cm furuncles draining purulent fluid. Lesions were predominantly on his lower extremities, but also on the trunk, head/neck, and upper extremities (). Histopathologic examination showed a moderately intense lymphocytic infiltrate within the pap...

Primary cutaneous CD30+ T-cell lymphoproliferative disorder presenting as paraphimosis: A case report and review of the literature.

Dermatol Online J — Wed, 10 Aug 2011 18:30:03 +0100

We report an unusual presentation of PC-ALCL. A 90-year-old, uncircumcised male presented with a 3-week history of painful penile swelling and discharge. The patient was treated with cephalexin and underwent emergent circumcision for paraphimosis. The diagnosis of ALCL was made on microscopic evaluation of the foreskin along with follow-up staging studies. A literature review revealed 31 previously reported cases of penile lymphoma, one of which reported a primary penile CD30+ T-cell lymphoma similar to ours. Only one case report described a lymphoma presenting as paraphimosis. Our case is the second reported case of PC-ALCL of the penis and the first of its kind to present as paraphimosis. Lymphomas must be included in the differential diagnosis of penile lesions and paraphimosis. When pr...

Histone deacetylase inhibitors in the treatment of hematological malignancies.

Bulletin du Cancer — Mon, 08 Aug 2011 23:00:00 +0100

Authors: Lemal R, Ravinet A, Moluçon-Chabrot C, Bay JO, Guièze R Abstract Histone deacetylases inhibitors (HDACi) represent a new epigenetic targeting therapy class, which is widely investigated in fundamental research and clinical trials. They are able to restore and increase tumor suppressor genes expression and to play an anti-tumoral activity through numerous targets, which are distributed all over the main differentiation, proliferation and survival cellular pathways. Their use in hematology led to vorinostat (SAHA) and romidepsin approval by FDA for the treatment of refractory cutaneous T-cell lymphomas. Preclinical and preliminary clinical results show a promising antineoplasic activity in most hematologic malignancies. This review will focus on the HDACi recent developmen...

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1

Leukemia — Thu, 04 Aug 2011 23:00:00 +0100

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1 Leukemia advance online publication, August 5, 2011. doi:10.1038/leu.2011.198 Authors: R C T McKenzie, C L Jones, I Tosi, J A Caesar, S J Whittaker & T J Mitchell (Source: Leukemia)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.

Biochemical Society Transactions — Sun, 31 Jul 2011 23:00:00 +0100

Authors: Edwards AJ, Pender SL IBDs (inflammatory bowel diseases) are lifelong manifestations that significantly impair the quality of life of those who suffer from them. Although many therapies are now available, including immunomodulatory drugs such as Infliximab which have efficacy in IBD, not all patients respond and some patients generate autoantibodies against these drugs. Hence the search for novel treatments is ongoing. HDACs (histone deacetylases) are responsible for condensation of chromatin in the nucleus of cells and inhibition of gene transcription and are often dysregulated during cancer. HDAC inhibitors allow normal gene transcription to be restored and provide attractive therapeutic options, as they have been shown to be anti-inflammatory and anti-proliferative in cance...

Thymus and activation-regulated chemokine in different stages of mycosis fungoides: Tissue and serum levels.

The Australasian Journal of Dermatology — Sun, 31 Jul 2011 23:00:00 +0100

Conclusion: Thymus and activation-regulated chemokine may be a marker for disease activity of mycosis fungoides, and may have a role in monitoring disease progression. PMID: 21834810 [PubMed - in process] (Source: The Australasian Journal of Dermatology)

NB‐UVB (311–312 nm)‐induced lentigines in patients with mycosis fungoides: a new adverse effect of phototherapy

Journal of the European Academy of Dermatology and Venereology — Tue, 26 Jul 2011 17:02:10 +0100

Conclusions Patients with MF treated with NB‐UVB may acquire lentigines. As opposed to PUVA‐induced lentigines which are a known common side‐effect of long‐term treatment, NB‐UVB‐induced lentigines are uncommon but appear earlier, even after a few months of treatment. (Source: Journal of the European Academy of Dermatology and Venereology)

Pathogenese der Mycosis fungoides

JDDG — Tue, 26 Jul 2011 16:49:52 +0100

(Source: JDDG)

A novel case of follicular mucinosis after autologous stem‐cell transplantation for multiple myeloma

Clinical And Experimental Dermatology — Tue, 26 Jul 2011 16:31:01 +0100

We report a novel case of FM developing after autologous stem‐cell transplantation for multiple myeloma, a correlation not previously reported in the literature. (Source: Clinical And Experimental Dermatology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Lymphomatoid papulosis: is a second lymphoma commoner among East Asians?

Clinical And Experimental Dermatology — Sun, 24 Jul 2011 23:00:00 +0100

Conclusions. LyP is a chronic, relapsing disease with considerable morbidity, but an overall good prognosis. A strikingly large proportion of our Asian patients (61.5%) had a second lymphoma, compared with previous studies. This emphasizes the importance of regular lifetime surveillance for associated lymphomas in all patients with LyP. (Source: Clinical And Experimental Dermatology)

C‐C chemokine receptor type 3 expression in lymphomatoid papulosis, but not in mycosis fungoides lesions from the same patient

Clinical And Experimental Dermatology — Sun, 24 Jul 2011 23:00:00 +0100

(Source: Clinical And Experimental Dermatology)

Simultaneous diagnosis of mycosis fungoides and dermatofibrosarcoma protuberans in a young patient: is it just a coincidence?

International Journal of Dermatology — Sat, 23 Jul 2011 16:18:30 +0100

(Source: International Journal of Dermatology)

A case of chronic inflammatory demyelinating polyneuropathy associated with immune-mediated thrombocytopenia and cutaneous T-cell lymphoma

Clinical Neurology and Neurosurgery — Fri, 22 Jul 2011 01:50:06 +0100

We present a patient with CIDP associated with ITP and cutaneous T-cell lymphoma. (Source: Clinical Neurology and Neurosurgery)

Yaupon Therapeutics, Inc. Appoints New Management Team

HSMN NewsFeed — Mon, 18 Jul 2011 13:29:14 +0100

New management to focus on NDA submission for proprietary gel formulation of mechlorethamine hydrochloride to treat early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma MALVERN, Pa.--(Healthcare Sales & Marketing Network)-- ... Biopharmaceuticals, PersonnelYaupon Therapeutics (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Primary cutaneous CD30 positive anaplastic large cell lymphoma – Report of a case treated with bexarotene

Leukemia Research — Mon, 18 Jul 2011 04:00:00 +0100

Primary cutaneous CD30+ lymphoproliferative disorders are the second most common cutaneous T-cell lymphomas (CTCL), accounting for approximately 25% of all cases . It comprises a large spectrum of clinical and histological entities, with papulosis lymphomatoides and CD30+ anaplastic large cell lymphoma (ALCL) in opposite extremes. (Source: Leukemia Research)

Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds.

Current Cancer Drug Targets — Thu, 14 Jul 2011 23:00:00 +0100

Authors: Blanquart C, François M, Charrier C, Bertrand P, Gregoire M Epigenetic modifications, such as DNA methylation or histone deacetylation, are early events in cell tumorigenesis. The consequences of these modifications are repression of gene transcription and, notably, of tumor suppressor gene transcription. New therapeutic strategies aim to 'normalize' the epigenetic status of cancer cells. Histone deacetylase inhibitors (HDACi) have shown promising effects against proliferation and resistance to apoptosis of a large number of cancer cells. Vorinostat (SAHA), a hydroxamate HDACi, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of refractory cutaneous T-cell lymphoma (CTCL). However, HDACi are poorly specific, present toxicities and many have v...

Primary cutaneous lymphomas: a reprisal

Seminars in Diagnostic Pathology — Tue, 12 Jul 2011 14:52:16 +0100

Primary cutaneous lymphomas (PCLs) are a group of lymphoid neoplasms provided with heterogeneous clinical, histological, immunohistochemical and molecular features. They can be classified in two groups: cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs). Recent studies show an increase of the incidence of PCLs over the last three decades. Our aim is to evaluate the commonest types of PCL analysing the clinical characteristics, histology, phenotype, molecular biology, prognosis and therapy. (Source: Seminars in Diagnostic Pathology)

Multicenter phase II trial of temozolomide in mycosis fungoides/Sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins.

Clinical Cancer Research — Sun, 10 Jul 2011 23:00:00 +0100

Authors: Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss FM, Kuzel TM AbstractPURPOSE: Temozolomide (TMZ) is an oral derivative of dacarbazine that induces DNA damage by methylating nucleotide bases. Resistance has been associated with high levels of O6-methylguanine-DNA methyltransferase (MGMT). Malignant CD4+ T-cells of patients with mycosis fungoides/Sézary syndrome (MF/SS) have been shown to have low levels of MGMT and may be particularly sensitive to this methylator.Experimental design: The efficacy of TMZ was evaluated in a multicenter phase II trial of patients with advanced stages of MF/SS. TMZ was given orally at daily doses of 200 mg/m2 for 5 days every 28 days. MGMT and mismatch repair protein expression was assessed by quantitativ...

Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark.

Acta Oncologica — Thu, 07 Jul 2011 23:00:00 +0100

Conclusion. In conclusion, the present study confirms that high-dose TSEBT is an effective, but generally not a curative therapy in the management of CTCL. High-dose treatment yielded significantly better results than low-dose treatment with 4 Gy. TSEBT offers significant palliation in most patients when other skin-directed or systemic treatments have failed. PMID: 21736502 [PubMed - as supplied by publisher] (Source: Acta Oncologica)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Up-Regulation of the Chemokine CCL18 by Macrophages Is a Potential Immunomodulatory Pathway in Cutaneous T-Cell Lymphoma.

The American Journal of Pathology — Wed, 06 Jul 2011 23:00:00 +0100

In this study, we show by PCR analysis and immunofluorescence staining that the chemokine CCL18 is present in skin biopsy specimens of patients with MF and its precursor form parapsoriasis en plaque but not in healthy tissue. In addition, the serum levels of CCL18 were increased threefold in MF patients compared with those in healthy controls. In skin, CCL18 was specifically expressed by CD163(+) CD209(+) macrophages at the invasive margin of the tumor and not expressed by mature CD208(+) dendritic cells in the center of the tumor. The chemokine CCL17 was, by contrast, ubiquitously expressed. Furthermore, CCL18 promoted the chemotaxis but not the proliferation of CTCL cells. CCL18 inhibited proliferation of tumor cells and abolished the CXCL12-induced growth of a CTCL cell line. These data...

Erythema gyratum repens‐like eruptions with large cell transformation in a patient with mycosis fungoides

International Journal of Dermatology — Mon, 04 Jul 2011 23:00:00 +0100

(Source: International Journal of Dermatology)

Mycosis fungoides: case report treated with radiotherapy

Anais Brasileiros de Dermatologia — Sun, 03 Jul 2011 18:03:30 +0100

This study reports the case of patient with multiple tumor lesions in the skin already biopsied with diagnosis of mycosis fungoides. The patient was refractory to both treatments with topical chemotherapy and phototherapy. It was then indicated total skin irradiation with electrons (Source: Anais Brasileiros de Dermatologia)

Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation.

Transplant Immunology — Fri, 01 Jul 2011 23:00:00 +0100

Authors: Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, Scheid C, Chemnitz J, Stadler R, von Bergwelt-Baildon M, Theurich S PMID: 21745569 [PubMed - as supplied by publisher] (Source: Transplant Immunology)

Unusual variants of mycosis fungoides.

Skinmed — Fri, 01 Jul 2011 04:00:00 +0100

Authors: Abeldaño A, Arias M, Benedetti A, Ochoa K, Maskin M, Pellerano G, Kien MC, Chouela E Abstract Unusual variants of mycosis fungoides (MF) differ substantially from the classical presentation, and most of them resemble other dermatologic diseases. The authors reviewed files of patients with MF who consulted our clinic between November 1995 and June 2010 to evaluate the relative frequency and clinical behavior of these variants. Among 98 patients with MF, 32 (32.65%) had unusual variants. The most common types included follicular MF (31.25%), hypopigmented MF (18.75%), poiquilodermic MF (15.6%), and erythrodermic MF (12.5%). Less common variants included unilesional MF, bullosa MF, ichthyosiform MF, granulomatous slack skin, and pigmented purpura-like MF. Progressive disease...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cruel to Be Kind: Genomic Exacerbation of Lipid Defect in Yeast Suggests New Therapy for a Pediatric Neurodegenerative Disease♦ [Papers of the Week]

Journal of Biological Chemistry — Thu, 30 Jun 2011 23:00:00 +0100

♦ See referenced article, J. Biol. Chem. 2011, 286, 23842–23851 Genome-wide assessments can allow for unbiased investigation into the genetic basis of disease, but it takes careful, hypothesis-driven experimentation to elucidate pathophysiological mechanisms that may succumb to therapeutic intervention. This duality of approaches resonates beautifully in the JBC Paper of the Week from Munkacsi et al. The authors screened a yeast model of Niemann-Pick type C (NP-C) disease, characterized by the aberrant trafficking and cellular storage of cholesterol, to identify a dozen or so etiologically relevant genes, including two that are essential to the genomic balance of histone acetylation. Accordingly, the researchers found that a number of cell lines from NP-C patients indeed manifest up-re...

Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas

Cancer Genetics and Cytogenetics — Thu, 30 Jun 2011 23:00:00 +0100

Chromosomal aberrations involving T-cell receptor (TCR) gene loci have been described in several T-cell malignancies. In primary cutaneous T-cell lymphomas (CTCL), the frequency of these aberrations has not yet been well established. We analyzed TCR gene loci (TCRAD, TCRB, and TCRG) status in CTCLs by fluorescence in situ hybridization (FISH). Twenty-five patients with CTCLs were included in the study: 13 Sézary syndromes (SS), six tumoral stage mycosis fungoides (MFt), and six primary cutaneous anaplastic large cell lymphomas CD30+ (cALCL-CD30+). FISH was performed with three break-apart probes flanking TCRAD (14q11), TCRB (7q34), and TCRG (7p14) loci in each case. TCR gene chromosomal rearrangements were not detected in any of the analyzed cases. Gains of TCRB and TCRG genes were observ...

Longitudinal lift biopsy technique with flat fixation for the diagnosis of mycosis fungoides

International Journal of Dermatology — Mon, 27 Jun 2011 18:02:00 +0100

(Source: International Journal of Dermatology)

An ultrastructural examination of a blistering lesion of mycosis fungoides bullosa

British Journal of Dermatology — Mon, 27 Jun 2011 17:59:27 +0100

(Source: British Journal of Dermatology)

Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients

Medical Oncology — Mon, 27 Jun 2011 17:50:07 +0100

This study aims to analyze the clinical prognostic factors in patients with T/NKCL. From January 1999 to December 2009, a total of 170 patients with T/NKCL, except mycosis fungoides, were included in this retrospective study. The diagnosis was established according to World Health Organization classification. The clinical characteristics and prognostic factors were evaluated. Of the 170 patients, mainly peripheral T-cell lymphoma-unspecified (65 cases), precursor T-lymphoblastic lymphoma/leukemia (31 cases) and nasal NK/T-cell lymphoma (NKTCL, 19 cases), advanced disease (Ann Arbor stages III–IV) was presented in 68.8% and extranodal involvement was in 71.2% of the patients. According to the international prognostic index (IPI), 77 cases were categorized as high/intermediate or hig...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Human herpesvirus 8 is not detectable in lesions of large plaque parapsoriasis, and in early-stage sporadic, familial, and juvenile cases of mycosis fungoides

Journal of the American Academy of Dermatology — Mon, 27 Jun 2011 04:00:00 +0100

Conclusion: The results of this study, conducted in a region relatively endemic for HHV 8, support most earlier studies showing a lack of association of HHV 8 infection with LPP and sporadic adult-type MF. To our knowledge, the lack of association of HHV 8 infection with juvenile and familial MF has not been previously reported. (Source: Journal of the American Academy of Dermatology)

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome

Annals of Oncology — Wed, 22 Jun 2011 23:00:00 +0100

Conclusion: Allogeneic HSCT can produce long-term remissions in relapsed/refractory T-cell lymphoma, especially those with nodal histologies. (Source: Annals of Oncology)

Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma

Annals of Oncology — Wed, 22 Jun 2011 23:00:00 +0100

Conclusions: Elevated LDH level and involvement of the paranasal sinus are two risk factors for CNS involvement in patients with PTCLs. Considering the poor prognoses after CNS relapse, prophylaxis should be considered with the presence of any risk factor. (Source: Annals of Oncology)

Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology — Sat, 18 Jun 2011 16:31:41 +0100

To the Editor: Patients with stage IA mycosis fungoides have a 96% survival rate at 5 years and are usually treated with topical medications or phototherapy. On the other hand, advanced cutaneous T-cell lymphoma (CTCL) has a worse prognosis, with a 5-year survival less than 30% for patients diagnosed with stage IV disease. Therefore, advanced CTCL typically requires systemic therapy. (Source: Journal of the American Academy of Dermatology)

FDA Grants Accelerated Approval Of ISTODAX(R) As Treatment For Patients With Peripheral T-Cell Lymphoma Who Have Received At Least One Prior Therapy

Health News from Medical News Today — Fri, 17 Jun 2011 11:00:00 +0100

Celgene Corporation (Nasdaq:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its Supplemental New Drug Application (sNDA) for an additional indication for ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. ISTODAX is also approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer [SPECIAL ARTICLE]

Journal of Clinical Oncology — Wed, 15 Jun 2011 23:00:00 +0100

This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS. (Source: Journal of Clinical Oncology)

The frequency of dual TCR‐PCR clonality in granulomatous disorders

Journal of Cutaneous Pathology — Mon, 06 Jun 2011 23:00:00 +0100

Conclusions: The use of dual TCR‐PCR analysis, that is, T‐cell clonality analysis in biopsy specimens from two different sites, serves as an adjunct to assist in distinguishing granulomatous inflammatory reactions from granulomatous T‐cell lymphoma, including granulomatous mycosis fungoides. The occasional finding of a T‐cell clone in a granulomatous dermatitis underscores the importance of clinicopathological correlation in daily diagnosis.Dabiri S, Morales A, Ma L, Sundram U, Kim YH, Arber DA, Kim J. The frequency of dual TCR‐PCR clonality in granulomatous disorders. (Source: Journal of Cutaneous Pathology)

In vitro Anti-angiogenic Properties of LGD1069, a Selective Retinoid X-Receptor Agonist through down-regulating Runx2 Expression on Human Endothelial Cells

BMC Cancer — Mon, 06 Jun 2011 23:00:00 +0100

Conclusions: Our results suggested that LGD1069 may impair angiogenic and metastatic potential induced by tumor cells through suppressing expression of Runx2 directly on human endothelial cells, which may point out new pathway through which LGD1069 display anti-angiogenic properties, and provide new molecular evidence to support LGD1069 as a potent anti-metastatic agent in cancer therapy. (Source: BMC Cancer)

Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters.

Clinical Cancer Research — Mon, 06 Jun 2011 23:00:00 +0100

CONCLUSION: These results indicated that transcriptional upregulation of BH3-only proteins plays an important role in the antitumoral activity of vorinostat in MCL, and that HDACi alone or in combination with BH3-mimetizing agents may represent a promising therapeutic approach for MCL patients. Clin Cancer Res; 17(12); 3956-68. ©2011 AACR. PMID: 21652541 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood — Wed, 01 Jun 2011 23:00:00 +0100

This study has been registered at clinicaltrials.gov as NCT00007345. (Source: Blood)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Rotherham photopheresis unit: Our first “Patient Day”

Transfusion and Apheresis Science — Tue, 31 May 2011 23:00:00 +0100

The nurse lead photopheresis unit at Rotherham General Hospital in the UK has been operating since 1994 and recently became a Centre of Excellence. It accepts referrals from Yorkshire, Scotland, Birmingham, Leeds and Manchester. Patients at the Rotherham photopheresis unit are primarily treated for steroid refractory Chronic Graft versus Host Disease (CGvHD) and Cutaneous T-cell Lymphoma (CTCL). The treatment received is Extracorporeal Photopheresis (ECP). This unit has been involved in research programmes lead by the consultant haematologist, from which data on the positive effect of ECP on patients with CGvHD has been identified. Data on CTCL has still to be formally presented. (Source: Transfusion and Apheresis Science)

Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India.

World Journal of Pediatrics : WJP — Tue, 31 May 2011 23:00:00 +0100

CONCLUSIONS: The distribution of different subtypes of lymphoma in pediatric and adolescent NHL in India differs considerably from that in western countries and other eastern countries. PMID: 21633853 [PubMed - as supplied by publisher] (Source: World Journal of Pediatrics : WJP)

Proteome and cytokine serum profiling to diagnose a mycosis fungoides

Proteomics. Clinical Applications — Tue, 31 May 2011 23:00:00 +0100

Conclusion and clinical relevance IP‐10 may be considered as a promising biomarker for the differentiation between mycosis fungoides and other skin conditions. (Source: Proteomics. Clinical Applications)

Small bowel obstruction due to mycosis fungoides: an unusual presentation.

The American Journal of the Medical Sciences — Tue, 31 May 2011 12:15:20 +0100

In this study, the authors present an 89-year-old woman diagnosed with T1, N0, B1, M0; stage 1A MF, treated with topical temovate with good response who presented 3 months later with small bowel obstruction due to biopsy-proven localization of MF in the gastrointestinal tract. PMID: 21613936 [PubMed - in process] (Source: The American Journal of the Medical Sciences)

OncoSec Medical To Initiate Multiple Phase II Skin Cancer Clinical Trials

Health News from Medical News Today — Fri, 27 May 2011 07:00:00 +0100

OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced it will initiate three Phase II clinical trials to assess its cancer-destroying, tissue-sparing ElectroImmunotherapy technology in patients with melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. OncoSec's lead ElectroImmunotherapy candidate for these trials is a DNA plasmid coding for IL-12 that is delivered using electroporation... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Discussion about the existence of unilesional form of mycosis fungoides

Anais Brasileiros de Dermatologia — Sat, 21 May 2011 16:16:18 +0100

A síndrome de Barraquer-Simons, também denominada lipodistrofia parcial progressiva ou lipodistrofia céfalo-torácica, caracteriza-se por perda progressiva do tecido celular subcutâneo, em direção crânio-caudal, de modo simétrico, iniciando na face e envolvendo progressivamente o tronco, membros superiores e inferiores, até as coxas. Nesse trabalho, relata-se o caso de paciente, com síndrome de Barraquer-Simons, sem associação com comorbidades sistêmicas.Barraquer-Simons syndrome, also called acquired partial lipodystrophy or cephalothoracic lipodystrophy, is a rare form of progressive lipodystrophy, characterized by symmetrical lipoatrophy of subcutaneous adipose tissue starting in the head and spreading to the thorax, upper and lower limbs and thighs. In this work, we report...

Skeletal muscle involvement in early-onset mycosis fungoides

Journal of the American Academy of Dermatology — Wed, 18 May 2011 16:52:08 +0100

We report a case of early-onset mycosis fungoides with involvement of skeletal musculature adjacent to cutaneous plaques that revealed a remarkable prolonged clinical course. (Source: Journal of the American Academy of Dermatology)

The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides [Study]

Archives of Dermatology — Sun, 15 May 2011 23:00:00 +0100

Conclusions A TSEBT of 30 Gy or greater is highly effective in treating T2-T3 MF, with better outcomes in T2 disease. There was no clinical advantage to adjuvant HN2 as used in our cohort. Second courses of TSEBT are safe and efficacious and provide clinically meaningful palliation for select patients. (Source: Archives of Dermatology)

Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer

HSMN NewsFeed — Mon, 09 May 2011 23:06:24 +0100

Chairman of Vicept Therapeutics, Tullman formerly served as co-founder, President and CEO of Ception Therapeutics, acquired by Cephalon Yaupon to focus on submission of NDA for proprietary mechlorethamine gel for early stage Cutaneous T-Cell Lymphoma (C... Biopharmaceuticals, PersonnelYaupon Therapeutics (Source: HSMN NewsFeed)

Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology — Sun, 08 May 2011 23:00:00 +0100

Conclusion: LAHS is probably underdiagnosed in CTCL patients with acute inflammatory symptoms suggestive of infections but should be considered, especially when cytopenia and elevated triglyceride and ferritin levels are present. (Source: Journal of the American Academy of Dermatology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effect of Chemokine Receptors CCR7 on Disseminated Behavior of Human T cell Lymphoma: clinical and experimental study

Journal of Experimental and Clinical Cancer Research — Fri, 06 May 2011 23:00:00 +0100

Conclusions: High CCR7 expression in T-NHL cells is significantly associated with lymphatic and distant dissemination as well as with tumor cell migration and invasion in vitro. Its underlying mechanism probably involves the PI3K/Akt signal pathway. (Source: Journal of Experimental and Clinical Cancer Research)

SID: Low-Dose Radiation Works in Mycosis Fungoides (CME/CE)

MedPage Today Meeting Coverage — Fri, 06 May 2011 18:43:03 +0100

PHOENIX (MedPage Today) -- Mycosis fungoides lesions improved quickly and extensively in 15 of 16 patients enrolled in a small clinical trial of low-dose total skin electron beam therapy. (Source: MedPage Today Meeting Coverage)

Molecular Markers Associated with Clinical Response to Bexarotene Therapy in Cutaneous T-cell Lymphoma.

Acta Dermato-Venereologica — Thu, 05 May 2011 23:00:00 +0100

This study explored the usefulness of a novel cancer-associated gene, NAV3 and corresponding chromosome 12 copy numbers as possible biomarkers to monitor the therapeutic response to bexarotene in 21 Finnish patients with CTCL. Six patients (29%) reached complete remission (CR) and 3 of these remained in CR for more than 24 months, 12 (57%) reached a partial response (PR, with one stable disease) and 3 were non-responders. Low-level NAV3 deletions were detected using a fluorescence in-situ hybridization (FISH) assay in the lesions of 5 patients, 4 of whom were non-responders or progressed after short PR. This occurrence of NAV3 deletions was statistically significant compared with non-progressors (p = 0.011, Fisher's exact test). Chromosome 12 tetraploidy was found in the lesions of two...

Survival Data for 299 Patients with Primary Cutaneous Lymphomas: A Monocentre Study.

Acta Dermato-Venereologica — Thu, 05 May 2011 23:00:00 +0100

Authors: Hallermann C, Niermann C, Fischer RJ, Schulze HJ The aim of this study was retrospectively to assess the validity of the 2005 WHO-EORTC classification for primary cutaneous lymphomas (PCL) in a large cohort of patients of a single German skin cancer unit. All patients with PCLs consecutively visiting our hospital between January 1980 and December 2005 were included in a retrospective monocentre study, analysing their histological and clinical data. A total of 312 patients fulfilled the inclusion criteria for PCL. In 299 patients clinical information and paraffin material were sufficient for detailed classification. Of the 299 patients, 63% expressed a T-cell and 37% a B-cell phenotype. Mycosis fungoides was the entity with the highest frequency (30.9%), followed by primary cut...

Hypercalcemia with extraosseous MDP uptake in a bone scan as initial presentation in a case of cutaneous T-cell lymphoma

Journal of Cancer Research and Therapeutics — Wed, 04 May 2011 23:00:00 +0100

Shanmuga Sundaram Palaniswamy, S Padma, Vijay Harish, Jay Kumar RaiJournal of Cancer Research and Therapeutics 2011 7(1):72-74A middle-aged lady presented with headache, vomiting of sudden-onset with intermittent evening rise of temperature. She also had slurring of speech with no loss of consciousness or altered sensorium. The patient was under evaluation for hypercalcemia. A whole body bone scan was done to look for causes of hypercalcemia and the scan showed extraosseous 99m Tc MDP (Technetium Methylene Di Phosphonate) uptake. One of the causes of extraosseous MDP uptake is cutaneous T-cell lymphoma (CTCL). On close interrogation the patient gave a history of hypopigmented dermal patches for more than 2 years duration. The coexisting dermal patches raised suspicion of CTCL. Skin biopsy ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Extra‐nodal non‐Hodgkin‐lymphoma with an acneiform eruption: folliculotropic mycosis fungoides

European Journal of Haematology — Sat, 30 Apr 2011 23:00:00 +0100

(Source: European Journal of Haematology)

Cutaneous T-Cell/Histiocyte-Rich B-Cell Lymphoma: A Case Report and Review of the Literature

Karger Publishers — Fri, 29 Apr 2011 16:09:21 +0100

Dermatology (DOI:10.1159/000327376) (Source: Karger Publishers)

Papular Mycosis Fungoides: A New Clinic Variant of Early and Benign Mycosis Fungoides? [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Thu, 28 Apr 2011 23:00:00 +0100

(Source: Journal of Clinical Oncology)

Poikilodermatous mycosis fungoides: A study of its clinicopathological, immunophenotypic, and prognostic features

Journal of the American Academy of Dermatology — Thu, 28 Apr 2011 23:00:00 +0100

Conclusion: Poikilodermatous MF represents a distinct clinicopathological entity from classic patch/plaque MF. It presents at a younger age and is more frequently associated with lymphomatoid papulosis. There is an increased number of cases with predominantly CD8+ CD4– atypical lymphocytes. Overall there is a good response to phototherapy and the overall prognosis appears favorable. (Source: Journal of the American Academy of Dermatology)